Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University
• Treatments: Entecavir

Criteria

Inclusion Criteria:

• treatment-naive patients with lymphoma

• HBsAg negative/HBcAb positive/hepatitis B virus DNA negative at baseline

• treated with chemotherapy and/or immunosuppressive therapy

• life expectancy of more than 3 months

Exclusion Criteria:

• younger than 18 years old

• HBsAg positive or HBcAb negative or hepatitis B virus DNA positive at baseline

• pregnant or lactating women